NCT05883449
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05883449
Title Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)
Acronym LuminICE-203
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Affimed GmbH
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
O'Neal Comprehensive Cancer Center at UAB Birmingham Alabama 35294 United States Details
City of Hope National Medical Center Duarte California 91010 United States Details
UC Irvine Health Orange California 92868 United States Details
Sarah Cannon Research Institute Denver Colorado 80218 United States Details
Norton Cancer Institute Louisville Kentucky 40207 United States Details
Beth Israel Deaconess Medical Boston Massachusetts 02215 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Masonic Cancer Center, University of Minnesota Minneapolis Minnesota 55455 United States Details
Washington University School of Medicine St Louis Missouri 63110 United States Details
John Theurer Cancer Center Hackensack New Jersey 07601 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
UNC Immunotherapy Team, University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field